RxDoctor Payments Data

Aron Schlau, MD

Internal Medicine · Palm Harbor, FLNPI 1902868904

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,100 of the $2,199 with a category attached, or 95.5%. Eli Lilly accounts for 95.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $2,100 and has fallen 97.5% since, to $52 in 2025.

$2,199in general payments, 2019–2025

Across 5 payments — averaging $439.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2K
  • Medtronic$30
  • Lilly USA, LLC$26
  • Merck$26
  • Novo Nordisk$17
$424,326in research payments, 2019–2025

Across 1,847 payments — averaging $229.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$180K
  • Abbott$99K
  • Sanofi US Services Inc.$61K
  • Eli Lilly$25K
  • Rhythm Pharmaceuticals, Inc.$10K
  • Teva Pharmaceuticals USA, Inc.$9K
  • plus $40K from 6 others

What the payments were for

  • Speaking & faculty fees$2,10096%
  • Food & beverage$994%

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly1$2,100
Medtronic1$30
Lilly USA, LLC1$26
Merck1$26
Novo Nordisk1$17

How this compares

$2,199 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$35,188
Medicare patients
115
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate34$26,182
EliquisApixaban16$11,887
SymbicortBudesonide/Formoterol Fumarate15$5,523
Gabapentin38$909
Atorvastatin Calcium129$794
Levothyroxine Sodium71$616
Rosuvastatin Calcium79$525
Metoprolol Succinate43$515
Duloxetine Hcl20$503
Pantoprazole Sodium45$369
Losartan Potassium65$344
Omeprazole37$329
Celecoxib17$293
Tamsulosin Hcl38$291
Propranolol Hcl14$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$26$26,18234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Palm Harbor

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →